The Effect of Palonosetron on the QTc Interval During Perioperative Period
NCT ID: NCT01650961
Last Updated: 2013-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2012-07-31
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Palonosetron
Intravenous administration of palonosetron 0.075 mg before the induction of general anesthesia
Palonosetron
0.075 mg IV as bolus before induction of general anesthesia
Control
Intravenous administration of normal saline before the induction of general anesthesia
Normal saline
2 ml normal saline as bolus before induction of general anesthesia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Palonosetron
0.075 mg IV as bolus before induction of general anesthesia
Normal saline
2 ml normal saline as bolus before induction of general anesthesia
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Clinically significant arrhythmias including atrial fibrillation
* Anti-emetics within 24 hours before surgery
* Steroids within 1 week before surgery
* Cancer chemotherapy or radiotherapy within 4 weeks before surgery
* Diabetes mellitus
* Pregnancy
* Patients receives a QT-prolonging drug
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kim HJ, Lee HC, Jung YS, Lee J, Min JJ, Hong DM, Choi EK, Oh S, Jeon Y. Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia. Br J Anaesth. 2014 Mar;112(3):460-8. doi: 10.1093/bja/aet335. Epub 2013 Oct 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YSJeon_palonosetron_QTc
Identifier Type: -
Identifier Source: org_study_id